Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 184 people in total — 85 with a condition called beta-thalassemia (a blood disorder affecting haemoglobin) and 99 with other rare anaemias (conditions where the blood cannot carry enough oxygen). The trial was measuring the safety of a medicine called deferasirox, which is used to remove excess iron from the body, as well as tracking how iron levels in the liver and blood changed over the course of the study. Not everyone finished the trial: 50 of the beta-thalassemia group and 37 of the rare anaemias group completed it. The reported data shows that, for the primary outcome — counting how many participants experienced any unwanted medical events (called adverse events) or serious adverse events, or died — all 85 beta-thalassemia participants and all 99 rare anaemias participants had at least one adverse event recorded. Serious adverse events (those involving hospitalisation, life-threatening situations, lasting disability, or death) were reported in 36 of the 85 beta-thalassemia participants and 50 of the 99 rare anaemias participants. Deaths were reported for 2 participants in the beta-thalassemia group and 12 in the rare anaemias group. For the secondary outcomes, the reported data shows that iron levels in the liver (measured by biopsy) fell by an average of 5.17 units in the beta-thalassemia group and 5.10 units in the rare anaemias group. A different liver iron measurement method showed a small average increase of 0.19 units in the beta-thalassemia group and a decrease of 2.04 units in the rare anaemias group. A blood marker of iron build-up called serum ferritin also changed over the study — starting at around 4,321 in the beta-thalassemia group and 3,269 in the rare anaemias group, and ending with average decreases of 612 and 382 units respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Rare Disease Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You must have already completed the full 12-month main part of this study.
- Female patients who have started their periods and are sexually active must be using two forms of contraception (such as two barrier methods, or a barrier method plus the pill), or must have had a hysterectomy, removal of the ovaries, or tubal ligation ("tubes tied").
- You (and/or your parent or legal guardian, if applicable) must have signed a written consent form agreeing to take part, following the rules of the country where the trial is taking place.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You cannot take part if you are currently pregnant.
- You cannot take part if you are currently breastfeeding.
Important: There may be additional eligibility requirements not listed here that the trial team will need to check — always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
The Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths
Other options
Data last synced from ClinicalTrials.gov: 13 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.